Molecular mass: 533.612 g/mol
Pralsetinib is a potent protein kinase inhibitor that selectively targets oncogenic RET fusions (KIF5BRET and CCDC6-RET). In non-small cell lung cancer (NSCLC), RET fusions are one of the main oncogenic drivers.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| GAVRETO Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| GAVRETO Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Pralsetinib is an active ingredient of these brands:
United States (US)Austria (AT)Croatia (HR)Ecuador (EC)Estonia (EE)France (FR)Ireland (IE)Israel (IL)Italy (IT)Lithuania (LT)Poland (PL)Romania (RO)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
